DUBLIN–(BUSINESS WIRE)–The “Bone
Cancer Treatment Market – Growth, Trends, and Forecast (2019 – 2024)”
report has been added to ResearchAndMarkets.com’s
offering.
The global bone cancer treatment market was valued at USD 62,865.6
million in 2018, and it is estimated to be valued at USD 83,770.9
million in 2024, while witnessing a CAGR of 4.93%. Certain factors that
are driving the market growth include increasing incidence of bone
cancer, and increasing government initiatives for bone cancer awareness.
The incidences of bone cancer are on a steady rise and need to be wisely
addressed at the earliest, in order to reduce the burden of bone sarcoma
across the world.
According to the estimates by American Society of Clinical Oncology, the
United States was expected to witness 3,450 new cases of bone cancer,
and an expected 1,590 deaths due to bone cancer in 2018.
Moreover, it is important to assure timely diagnosis and treatment, in
order to increase the survival rate. Many government organizations are
taking initiatives to increase awareness about bone cancer. For
instance, the UK Government formed an organization named Genomics
England, post the launch of 100,000 Genomes Project in 2012. Genomic
England is responsible for sequencing 100,000 genomes from 700,000
genomes of NHS-registered patients.
However, the chemotherapeutic drugs approved for the treatment of bone
cancer do not have an effective treatment regime, as it always varies
according to the prevailing conditions, and the way the patient’s body
responds to the drug. The associated side effects, risks, and
limitations of the treatment are limiting the growth of the global bone
cancer treatment drugs market.
Key Market Trends
Osteosarcoma is Expected to Hold the Largest Market Share in the
Primary Bone Cancer Type
In the bone cancer type segment of the bone cancer treatment market,
among all primary bone cancers, osteosarcoma is expected to have largest
market size, and is likely to witness a CAGR of 6.31% over the forecast
period.
Osteosarcoma is the most common type of cancer affecting bones, and it
mostly occurs in children and young adults. Based on the cells,
osteosarcoma is classified as high-, intermediate- and low-grade.
According to the American Cancer Society, about 800 to 900 new cases of
osteosarcoma are diagnosed in the United States every year, with about
half of these occurring in children and teenagers.
Research on osteosarcoma is done at various medical centers, university
hospitals, and other institutions across the world. Many advancements
have taken place in the treatment of osteosarcoma in the past few
decades. Osteosarcoma can be treated by surgery, radiation therapy,
chemotherapy, targeted therapy drugs, etc.
Thus, research related to the bone cancer treatment market is
increasing, owing to the high prevalence of osteosarcoma, globally.
North America Dominates the Market and is Expected to do Same in the
Forecast Period
North America currently dominates the bone cancer treatment market, and
it is expected to continue its stronghold for a few more years. This
region is expected to increase its market share in the future, owing to
the fact that, currently, in the region, mainly in the United States,
many clinical trials are underway for bone cancer therapies.
Some studies are testing new chemo drugs. Researchers are also looking
for new ways to use the existing approved drug portfolio. For instance,
doctors are studying whether adding a bisphosphonate called zoledronic
acid (Zometa) to the bone cement, which is used in filling the space
left after removing a giant cell tumor, may decrease the chances of that
tumor returning in that place.
Competitive Landscape
The global bone cancer treatment market is highly competitive and
consists of a considerable number of significant players. All of the
existing players in global bone cancer treatment market are either
legacy suppliers of treatment options, like chemotherapy and radiation
therapy, or are concentrating on clinical trials for novel bone cancer
approaches, including targeted therapy and immunotherapy.
Companies like Bayer AG, Amgen, Novartis AG, and Pfizer Inc., among
others, are expected to hold the substantial market share in the bone
cancer treatment market.
Various developments have recently been taking place in the market. For
example, in September 2016, Dr. Reddy’s Laboratories (DRL) expanded
strategic collaboration with Amgen to market and distribute Xgeva
(denosumab), Vectibix (panitumumab), and Prolia (denosumab) in India.
Topics Covered
1 Introduction
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Dynamics
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Bone Cancer
4.2.2 Increasing Government Initiatives for Bone Cancer Awareness
4.3 Market Restraints
4.3.1 Unavailability of Effective Treatment and Side Effects
4.3.2 High Cost of Cancer Therapies
4.4 Porter’s Five Forces Analysis
5 Market Segmentation
5.1 Bone Cancer Type
5.1.1 Primary Bone Cancer
5.1.1.1 Osteosarcoma
5.1.1.2 Chondrosarcoma
5.1.1.3 Ewing Tumour
5.1.1.4 Fibrosarcoma and Malignant Fibrous Histiocytoma
5.1.1.5 Giant Cell Tumour of Bone
5.1.1.6 Chordoma
5.1.2 Secondary Bone Cancer (Metastatic Bone Cancer)
5.2 Treatment Type
5.2.1 Chemotherapy
5.2.1.1 Doxorubicin
5.2.1.2 Cisplatin
5.2.1.3 Cyclophosphamide
5.2.1.4 Etoposide
5.2.1.5 Other Chemotherapies
5.2.2 Targeted Therapy
5.2.2.1 Denosumab
5.2.2.2 Imatinib
5.2.3 Radiation Therapy
5.2.4 Surgery
5.3 Geography
5.3.1 North America
5.3.2 Europe
5.3.3 Asia-Pacific
5.3.4 Middle East & Africa
5.3.5 South America
6 Competitive Landscape
6.1 Company Profiles
6.1.1 Amgen
6.1.2 Baxter
6.1.3 Bayer AG
6.1.4 Hikma Pharmaceuticals
6.1.5 Johnson & Johnson
6.1.6 Novartis AG
6.1.7 Pfizer Inc.
6.1.8 Recordati Group
6.1.9 Takeda Pharmaceutical Company
7 Market Opportunities and Future Trends
For more information about this report visit https://www.researchandmarkets.com/research/8l55nd/bone_cancer?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs